Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Resmed Inc (NY: RMD )

243.78 +0.18 (+0.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 551,443
Open 243.60
Bid (Size) 233.15 (1)
Ask (Size) 246.97 (1)
Prev. Close 243.60
Today's Range 241.44 - 243.88
52wk Range 151.95 - 260.49
Shares Outstanding 146,234,244
Dividend Yield 0.87%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year
ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth. 
Via Investor's Business Daily
Why Quality-Oriented Investors Should Consider NYSE:RMD.
Exploring RESMED INC (NYSE:RMD)'s quality characteristics. 
Via Chartmill

Performance

YTD
+41.91%
+41.91%
1 Month
+2.69%
+2.69%
3 Month
+7.56%
+7.56%
6 Month
+14.31%
+14.31%
1 Year
+58.42%
+58.42%

More News

Read More
ResMed Announces Participation in the UBS Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
P/E Ratio Insights for ResMed
Via Benzinga
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
Via Investor's Business Daily
Cracking The Code: Understanding Analyst Reviews For ResMed
Via Benzinga
Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?
Via Benzinga
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
Via Benzinga
My 3 Favorite Stocks to Buy Right Now
Via The Motley Fool
A Peek at ResMed's Future Earnings
Via Benzinga
Is RESMED INC (NYSE:RMD) suited for quality investing?
Via Chartmill
Expert Outlook: ResMed Through The Eyes Of 7 Analysts
Via Benzinga
Obesity Drugs-Tied ResMed Edges Higher On Quarterly Beat
Via Investor's Business Daily
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025
From ResMed Inc.
Via GlobeNewswire
ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024
From ResMed Inc.
Via GlobeNewswire
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns
From ResMed Inc.
Via GlobeNewswire
UPDATE -- ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health
From ResMed Inc.
Via GlobeNewswire
UPDATE -- ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
From ResMed Inc.
Via GlobeNewswire
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
From ResMed Inc.
Via GlobeNewswire
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health
From ResMed Inc.
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 21
Via Talk Markets
Why ResMed Stock Tumbled by 5% Today
Via The Motley Fool
Stocks Edge Lower As Fed Rate Decision Looms, Treasury Yields Rise As Odds Improve For Smaller Cut: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange
From ResMed Inc.
Via GlobeNewswire
Vaping Expected to Increase COPD Health and Economic Burden by 2050
From ResMed Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.